The announcement of positive trial results often leads to an increase in a company's stock price, as it indicates progress in the company's product pipeline and brings it one step closer to potential regulatory approval and market launch. In this case, CTx-1301 is a key drug in Cingulate Therapeutics' pipeline, and positive trial results could therefore have a significant impact on the company's stock.